(Q38023882)

27 August 2017

Systematic review: hypomagnesaemia induced by proton pump inhibition (English)

1 reference

27 August 2017

1 reference

M W Hess

1

1 reference

27 August 2017

J G J Hoenderop

series ordinal

2

1 reference

27 August 2017

R J M Bindels

series ordinal

3

1 reference

27 August 2017

J P H Drenth

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

4 July 2012

1 reference

Alimentary Pharmacology & Therapeutics

27 August 2017

1 reference

27 August 2017

36

1 reference

27 August 2017

5

1 reference

27 August 2017

405-413

1 reference

The effects of high-dose esomeprazole on gastric and oesophageal acid exposure and molecular markers in Barrett's oesophagus.

27 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

The site of action of pantoprazole in the gastric H+/K(+)-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Overprescribing proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Systematic review of the risk of enteric infection in patients taking acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Increase in vertebral fracture risk in postmenopausal women using omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Uses of proton pump inhibitors and hypomagnesemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Tetany secondary to the use of a proton-pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Is there a dark side to long-term proton pump inhibitor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Adverse effects of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

The effect of proton pump-inhibiting drugs on mineral metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Omeprazole and refractory hypomagnesaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Severe hypomagnesaemia in long-term users of proton-pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Severe hypomagnesemia during long-term treatment with a proton pump inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

A case series of proton pump inhibitor-induced hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Proton pump inhibitors and severe hypomagnesaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

How should hypomagnesaemia be investigated and treated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Hypomagnesemia and hypermagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Magnesium deficiency: Recognition and treatment in the emergency medicine setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Expression of renal distal tubule transporters TRPM6 and NCC in a rat model of cyclosporine nephrotoxicity and effect of EGF treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Calciotropic and magnesiotropic TRP channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Cisplatin and hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

Insights into the molecular nature of magnesium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

The importance of urinary magnesium values in patients with gut failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2012.05201.X

10.1111/J.1365-2036.2012.05201.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference